Lifesci Capital Analysts Raise Earnings Estimates for Savara

Savara Inc. (NASDAQ:SVRA) – Equities researchers at Lifesci Capital upped their FY2025 earnings estimates for Savara in a note issued to investors on Thursday, November 13th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings of ($0.53) per share for the year, up from their previous forecast of ($0.55). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara’s Q4 2025 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.49) EPS.

Savara (NASDAQ:SVRA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01).

A number of other brokerages have also recently weighed in on SVRA. Wells Fargo & Company started coverage on Savara in a report on Monday, October 20th. They set an “overweight” rating and a $7.00 price objective on the stock. Guggenheim upped their target price on Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Citigroup reissued an “outperform” rating on shares of Savara in a research note on Thursday, October 23rd. Oppenheimer boosted their price objective on shares of Savara from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.29.

Savara Trading Up 0.9%

Shares of SVRA opened at $4.30 on Monday. Savara has a 1-year low of $1.89 and a 1-year high of $4.51. The company has a market capitalization of $874.91 million, a P/E ratio of -8.60 and a beta of 0.45. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. The firm’s 50 day simple moving average is $3.81 and its 200 day simple moving average is $3.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. VR Adviser LLC grew its holdings in shares of Savara by 172.7% in the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after acquiring an additional 5,626,624 shares during the period. Bain Capital Life Sciences Investors LLC grew its stake in shares of Savara by 20.8% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock valued at $48,754,000 after purchasing an additional 3,035,164 shares during the period. Frazier Life Sciences Management L.P. grew its stake in shares of Savara by 32.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock valued at $31,751,000 after purchasing an additional 2,801,922 shares during the period. Rosalind Advisors Inc. increased its position in shares of Savara by 50.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after purchasing an additional 1,345,056 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in shares of Savara by 7.3% in the 1st quarter. Nantahala Capital Management LLC now owns 8,075,375 shares of the company’s stock worth $22,369,000 after purchasing an additional 550,116 shares during the period. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.